Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DR Thomas Staehelin had a heads up on covid way before any other country knew, before it became news! Because he is the WHO!!!
they had to pay for it in there notes!!!!!!! so sorry Dr. S :( GET THIS DONE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Wait on taxes Dr. S are you!!!
Do not give all of us bad hope here! NOW you pushed your time fame out, Sure there's always hope, But not from you! False lies does not cut it here!!!!!
IT'S TIME PUPPET MASTERS TO SHOW US WHAT MYMX HAS??????
PUPPET MASTER!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
https://hotcorn-cdn.s3.amazonaws.com/wp-content/uploads/sites/5/2019/04/16111054/REV-PuppetMasterTheLittliestReich-1.jpg
puppet masters dog crap / until they bring this to new highs, I will change it!
https://ak4.picdn.net/shutterstock/videos/1015461454/thumb/1.jpg
IT WOULD BE ABOUT TIME TO!!!!!!!!!!!!!!!!!!!!!!!
I wonder if he will show his face? :)
It's time for some news!! MYMX
Dr. Rogier Sanders at the Amsterdam Medical Center of the University of Amsterdam!!!!
Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination
Abbas Jamali 1, Marijke Holtrop, Aalzen de Haan, Hamidreza Hashemi, Mohammad Shenagari, Arash Memarnejadian, Farzin Roohvand, Farzaneh Sabahi, Masumeh Tavassoti Kheiri, Anke Huckriede
Affiliations collapse
Affiliation
1Influenza Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.
https://pubmed.ncbi.nlm.nih.gov/22981929/
Anke Huckriede ring a bell!!! J Wilschut, A Huckriede
Recombinant protein vaccines, a proven approach against ...
europepmc.org › article › MED
Jan 07, 2021 · For example, while it is known that Cuba’s Soberana 01 vaccine is based on the RBD antigen, additional details have not yet been widely published, although original news reports suggest that a combination with the proven outer membrane vesicle platform of the Cuban meningococcus B vaccine was planned . AdimrSC-2f is a vaccine candidate ...
Author: Jeroen Pollet, Wen-Hsiang Chen, Ulrich Strych
Cited by: 13
Recombinant protein vaccines, a proven approach against coronavirus pandemics.
Pollet J1, Chen WH1, Strych U1
Author information
Affiliations
3 authors
1. Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States of America; Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, 1102 Bates Street, Houston, TX, United States of America.
https://europepmc.org/article/MED/33421475
Cuba Soberana 02 COVID-19 Vaccine Description
Soberana 02 (FINLAY-FR-2) COVID-19 vaccine candidate is a conjugate vaccine in which the virus antigen, the receptor-binding domain (RBD), is chemically bound to the tetanus toxoid.
https://www.precisionvaccinations.com/vaccines/cuba-soberana-02-covid-19-vaccine
Iran and Cuba develop the first conjugate vaccine against covid-19
27 July 20210
Iran and Cuba use all the knowledge and platforms at their disposal to produce the world's first conjugate vaccine against COVID-19: PastuCovac
https://ciudadccs.info/2021/07/27/iran-y-cuba-desarrollan-la-primera-vacuna-conjugada-contra-covid-19/
Cuba’s Soberana 2 COVID-19 Vaccine – What is conjugate vaccine and how does it work?
Cuba's Soberana 02 vaccine is a conjugate vaccine which carries part of the spike protein from the virus, binding it to human cells. It is one of the three vaccines in the Soberana series.
SANGEETA NAIR
CREATED ON: JUL 13, 2021 14:53 IST
MODIFIED ON: JUL 13, 2021 14:53 IST
https://www.jagranjosh.com/current-affairs/cubas-soberana-2-covid19-vaccine-what-is-conjugate-vaccine-and-how-does-it-work-1626167243-1
Strategy to optimize the immune response to poverty related ...
www.who.int › phi › implementation
i. Conjugate to carrier protein (any) ii. Conjugate to virosomes iii. Conjugate to a virus (e.g alpha virus) iv. Express as fusion protein in self-assembling system (but NOT human virus origin i.e. not HBsAg, HBc, etc.) Select one of the above and test both monomeric and multimeric forms. 2) Selection of adjuvant and formulation
https://www.who.int/phi/implementation/INYVAX_WP2_D2-2_adjuvant_selection_strategy.pdf?ua=1
Influenza Vaccines for the Future | NEJM
www.nejm.org › doi › full
Covid-19; Keyword Advanced Search ... and the development of formulations that can be administered without a special nasal-spray device (i.e., nose drops). ... Que JU, Gluck R. A virosome vaccine ...
GLUCK!!!!!!!!!!!!!!!!!!!!!!!
https://www.nejm.org/doi/full/10.1056/NEJMra1002842
NOT SURE WERE IT IS IN THE ARTICLE?
Inhalable nanovaccine with biomimetic coronavirus structure ...
pubmed.ncbi.nlm.nih.gov › 33762883
The nanovaccine that mimic virosome is composed of poly(I:C) mimicking viral genetic material as immune adjuvant, biomimetic pulmonary surfactant (bio-PS) liposomes as capsid structure of virus and the receptor binding domains (RBDs) of SARS-CoV-2 as "spike" to completely simulate the structure of the coronavirus.
Chem Eng J
. 2021 Aug 15;418:129392. doi: 10.1016/j.cej.2021.129392. Epub 2021 Mar 19.
Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
https://pubmed.ncbi.nlm.nih.gov/33762883/
8 Best Nasal Sprays for COVID-19 (June 2021)
www.aestheticsadvisor.com › 2021 › 05
June 15, 2021: South Valley University in Egypt’s Clinical Trial Reveals Ivermectin-based Nasal Spray Improves COVID-19 Outcomes. May 22, 2021: Mexican randomized trial of prophylactic silver nanoparticle nasal spray/mouthwash (n=231) ends up with a very impressive 85% COVID-19 infection reduction
https://www.aestheticsadvisor.com/2021/05/nasal-spray-COVID-19.html
Where are you Mymetics?
News & Events / 5 July 2021
Bachmann Group Yacht Agency: Welcome to Guernsey!
Bachmann Group was founded in Guernsey in 1974 and remain based on the beautiful Channel Island to this day. For more than four decades, we have been offering services and assistance to the owners and crews of yachts that visit Guernsey and the nearby islands on Herm, Sark and Alderney.
https://bachmanngroup.com/bachmann-group-yacht-agency-welcome-to-guernsey
We are here Mr. K, We are not going away, Time to let us know where this company stands as of today!!!!!!
What do you have Kemper's? Where is the Big Bonanza? Time to show us what Mymetics Corporation has!!!!!!!
Mymetics likes to be on the ground floor of vaccine development. The company holds a portfolio of early-stage vaccines being developed to treat HIV, malaria, herpes, and other viruses. Its key technology uses lipid-like virosomes to carry a vaccine's active ingredients. The development-stage biotech has built its portfolio up through acquisitions, and hopes it can attract a major pharmaceutical partner once it has advanced a drug candidate through early stage clinical trials. Mymetics conducts its clinical testing in Europe and Africa. Its research and development activities take place at its facilities in Switzerland, where it also secures its funding from wealthy individuals.
https://www.dnb.com/business-directory/company-profiles.mymetics_sa.21a59dafae959f8332a19181e723e28a.html#contact-anchor
Table 1 Formulation properties of liposome and emulsion formulations of 3M-052.
From: A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
https://www.nature.com/articles/srep46426/tables/1
Results
Formulation Development of 3M-052 using LIPOSOMES
https://www.nature.com/articles/srep46426/#Sec2
STEVEN G REED :)
Mark Tomai
Head of Microneedle and Toll-like Receptor Business Development at 3M Drug Delivery Systems
St Paul, Minnesota
Experience
3M Drug Delivery Systems
Head of Toll-like Receptor and MIcroneedle Business Development
Company Name 3M Drug Delivery Systems
Dates Employed 2007 – Present
Employment Duration 14 yrs
3M Drug Delivery Systems Division
Head of Vaccine Business Development
Company Name 3M Drug Delivery Systems Division
Dates Employed 2007 – Present
Employment Duration 14 yrs
3M Pharmaceuticals
Division Scientist
Company Name3M Pharmaceuticals
Dates Employed 1991 – 2005
Employment Duration 14 yrs
Over 29 years experience in the Pharmaceutical Industry. During the last 1.5 years I have been in our Corporate Biomaterials group focusing on biopurification and development of toll-like receptor agonists. Prior to that I spent 12 years as the Head of Vaccine and Microneedle Business Development at 3M Drug Delivery Systems. Involved with outlicensing our toll-like receptor agonists to various vaccine companies for use as vaccine adjuvants and for use in treating cancer. Lead the partnering efforts focused around 3M's microneedle platform as well as deals focused on transdermal drug delivery. To date I have been involved with the signing of multiple deals in the vaccine adjuvant, oncology and microneedle/transdermal delivery system areas.
Previously, over 16 years experience in Discovery and Development of immunodulators for cancer, asthma/allergy and chronic viral infection. A proven ability in identifying drug candidates, preclinical development, preparation of INDs for clinical studies and NDAs for registration. Recognized for technical and leadership contributions, knowledge and abilities. A hands-on, thoughtful scientist, mentor and team member driven by scientific excellence and with the passion and skills to create and progress discovery projects to successful concept testing in clinic. A strong record of innovative scientific discoveries as evidenced by numerous invited lectures at national and international meetings, over 70 peer-reviewed publications and 12 issued patents.
linkedin
New horizons in adjuvants for vaccine development
Author links open overlay panel Steven GReed12 MarkTomai3 Michael JGaleJr.2
1
HDT Bio, Seattle, WA, United States
2
Center for Innate Immunity and Immune Disease, Department of Immunology, U of Washington School of Medicine, Seattle, WA, United States
3
3M, St. Paul, MN, United States
https://www.sciencedirect.com/science/article/abs/pii/S0952791520300844?via%3Dihub
Novel Immune Potentiators and Delivery Technologies for Next ...
link.springer.com › book › 10
Mark A. Tomai, John P. Vasilakos. ... Influenza Virosomes as Antigen Delivery System. Christian Moser, Mario Amacker. Pages 287-307. Matrix M Adjuvant Technology.
https://link.springer.com/book/10.1007/978-1-4614-5380-2
Adjuvant composition and delivery route shape immune response ...
www.nature.com › articles › s41541/018/0060-x
Jun 05, 2018 · Mark A. Tomai & James Elvecrog. TECHLAB, Inc., 2001 Kraft Drive, Blacksburg, VA, USA ... New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various ...
Author: Mayuresh M. Abhyankar, Mark T. Orr, Susan Lin, Mohammed O. Suraju, Adrian Simpson, Molly Blust, Tiep...
Cited by: 15
https://www.nature.com/articles/s41541-018-0060-x
New GMP manufacturing processes to obtain thermostable HIV-1 ...
www.nature.com › articles › s41541/020/0190-9
May 18, 2020 · Our thanks also to Mark Tomai from 3M Drug Delivery Systems Division for early discussions about the 3M-052 adjuvant and inputs, and all the other persons involved in the product development that ...
Author: Mario Amacker, Charli Smardon, Laura Mason, Jack Sorrell, Kirk Jeffery, Michael Adler, Farien Bhoela...
Cited by: 4
https://www.nature.com/articles/s41541-020-0190-9
New Technologies for Corey Casper, MD, MPH Accessible ...
www.idri.org › wp-content › uploads
IDRI Adjuvants Enable Broad Coronavirus Protection CONFIDENTIAL 13 SARS-CoV2 RBD Protein + IDRI / 3M adjuvant (3M052-Alum) generated higher nAb titers to mutant COVID strains compared with mRNA vaccine, and also conferred strong protection across coronaviruses
http://www.idri.org/wp-content/uploads/2021/04/IDRI-Technologies_Coronavirus.pdf
Infectious Disease Research Institute (IDRI), 1616 Eastlake ...
www.globalnpo.org › US › Seattle
Dec 03, 2020 · IDRI’s immune-enhancing adjuvant formulation, 3M052-Alum, proves successful in extending immunity against HIV. We are proud to partner with Mark Tomai at 3M Drug Delivery Systems, who discovered the 3M052 adjuvant, and Dr. Kastur and Dr. Ahmed at the Emory Vaccine Center as they begin phase 1 clinical trials.
Location: 1616 Eastlake Ave E, Ste 400, Seattle, 98102, WA
Phone: (206) 329-1106
https://www.globalnpo.org/US/Seattle/125756450839805/Infectious-Disease-Research-Institute-%28IDRI%29
Are you seeing promising results with the use of 3M-052 in COVID-19 vaccines?
https://www.3m.com/3M/en_US/health-care-us/stories/full-story/~/getting-a-boost-how-adjuvants-can-improve-vaccines-for-covid-19/?storyid=cc24495c-4632-4a07-9c65-bd5daf4ffb74
Welcome to the McElrath Lab
The McElrath laboratory applies multi-disciplinary and cross-platform approaches to their studies, which encompass the following research areas:
HIV Vaccine Trials Network (HVTN) Laboratory
Cape Town HVTN Immunology Laboratory
Seattle Vaccine Trials Unit (Seattle VTU)
Coronavirus, Malaria & Tuberculosis Vaccines
Infectious Diseases Clinical Research Consortium
CHAVD
Long Term Non-Progressor Cohort (LTNP)
https://research.fredhutch.org/mcelrath/en.html?_ga=2.176288611.735732399.1580147533-1610628307.1573860687
Covid
https://www.fredhutch.org/en/news/center-news/2021/04/coronavirus-research.html
I'm in this for Dollars and not a couple of bucks! Going to hold you to it!
If your talking a couple of bucks a share that would be great! WE WILL BE WAITING!! :)
Better get all the shares you can!! Myself and all here will hold you to the three or four weeeks!! And we want to see Dollars!! :)
Phase 1 trial begins for universal flu vaccine developed at UW
SEATTLE — In this lab at the University of Washington, researchers are exploring the possibilities of synthetic protein design.
One goal is to make a different and better flu shot known as the universal flu vaccine.
“The current flu vaccines are intended to target a small set of viruses. And our vaccine has been designed to instead target a broader families of viruses,” said Dan Ellis.
Ellis is a leading researcher at the UW Medicine Institute for Protein Design.
Using a computer model, he showed KIRO 7 how the vaccine is built by putting virus pieces on technology developed at the lab called the nanoparticle platform.
“So that if those strain predictions for the vaccine aren’t perfectly accurate, it can still provide protection and therefore be more reliable in the event of a bad flu season,” Ellis explained.
His lab has been working with the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center.
That’s part of the same agency Dr. Anthony Fauci leads.
Just this past week, Fauci testified before the House Appropriations Committee.
“What other progress has been made in the past year towards developing a universal flu vaccine?” asked Chairwoman Rose DeLauro (D-CT).
“Literally it just started today, a Phase 1 trial of what’s called a nanoparticle mosaic approach to its universal flu vaccine. So thank you for asking that question. This is what it looks like,” Fauci answered.
Ellis says the vaccine worked very well when it was tested on mice, ferrets and primates. The next step is testing it on people to see how safe it is.
The trial will include 40 people, half of whom get the experimental universal flu vaccine while the other half will get a standard flu shot.
The human trial is expected to last up to 2 years, so it will be quite some time before there’s even talk of bringing it to market.
But it’s an exciting time for Ellis and other scientists who are working on innovations that will impact global health.
“There’s a lot of potential to extend this technology to other diverse viral families such as coronaviruses, HIV and many other things,” Ellis added.
https://www.kiro7.com/news/local/phase-1-trial-begins-universal-flu-vaccine-developed-uw/J6IJQ4X7NZADBPWPJMDFNMMLMM/
This communication introduces VaxiPatch, a vaccination system that incorporates novel formulations of glycoprotein subunit vaccines, novel formulations of adjuvants and a novel microneedle array skin patch. As described here, subunit vaccines are produced by recombinant DNA methods in CHO or 293 cells and formulated into virosomes. Adjuvants are formulated with liposomes. Both are concentrated and printed onto microarrays yielding a room-temperature stable sugar glass.
For stability studies, concentrated formulated virosomes were prepared as they would be for VaxiPatch array printing (15% trehalose, 0.5% FD&C blue dye). This material was then deposited as 1 µL aliquots in open 0.5 mL microcentrifuge tubes, which were stored in sealed foil bags containing desiccant packs at 20 °C overnight to achieve initial drying. These bags were then segregated and stored at temperatures of 20, 40, or 60 °C. At designated time points, samples were unsealed, reconstituted in PBS, and subjected to SRID assay to determine the extent of remaining HA potency.
3.3. Incorporation of purified recombinant HA antigen into virosomes
To enhance immunogenicity of our recombinant antigen, purified full-length rHA was incorporated into virosomes by dialysis.
When applied without adjuvants, virosome-loaded VaxiPatches were comparable to the 15-fold higher-doses of IM injected material.
3.7. Stability of virosomes
Drying of vaccine antigens in a sugar glass state can allow for impressive levels of thermostability. We employed the industry-standard assay for HA-based vaccine potency, the single radial immunodiffusion assay (SRID) to investigate the potential of our virosomal rHA to retain activity without refrigeration.
Acknowledgements
We thank the UC Davis Venture Catalyst Program of which Verndari is a member. We thank the UC Davis Mouse Biology Program who performed the animal work. We thank Yeonju Song for early work on the VaxiPatch. This work was funded by Verndari, Inc.
Funding sources
This work was funded by Verndari Inc.
https://www.sciencedirect.com/science/article/pii/S0264410X20309580
VaxiPatch™
This work introduces VaxiPatch, a novel vaccination system comprised of subunit glycoprotein vaccine antigens, adjuvants and dermal delivery. For this study, rHA of influenza virus B/Colorado/06/2017 was incorporated into synthetic virosomes, and adjuvant liposomes were formed with QS-21 from Saponaria quillaja, with or without the synthetic TLR4 agonist 3D – (6-acyl) PHAD. These components were concentrated and co-formulated into trehalose with dye.
Non-adjuvanted VaxiPatches were also compared with rHA virosomes injected intramuscularly. Accelerated shelf life studies further suggest that formulated virosomal antigens retain activity for at least two months at 60° C. Further, co-formulation of a dye could provide a visible verification of delivery based on the temporary pattern on the skin. A room-temperature-stable vaccination kit such as VaxiPatch has the potential to increase vaccine use and compliance globally. Access the full publication here
https://www.pharmaexcipients.com/transdermal/vaxipatch-vaccination-system/
https://www.pharmaexcipients.com/?s=virosome
Toon Stegmann - Academia.edu
independent.academia.edu › ToonStegmann
Toon Stegmann studies Excipient, Indian Politics, and Biophysics.
https://independent.academia.edu/ToonStegmann
J.M. Bos (Jasper), E. Rietveld (Edwin), H.A. Moll (Henriëtte), E.W. Steyerberg (Ewout), W. Luytjes, J.C. Wilschut (Jan), R. de Groot (Ronald) and M.J. Postma (Maarten)
2007-09-28
The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach
https://repub.eur.nl/pub/35905
Jasper Bos was born in Groningen in 1995 where he started studying chemistry in 2013. There he obtained his B.Sc. in 2017 working on creating a dissipative RNA system in the group of Prof. Sijbren Otto. For his master thesis he returned to the Otto group to work on the development of the catalytic properties of peptide based replicators
http://otto-lab.com/people.htm#Jasper
Jasper Bos
General Partner at Forbion
Amsterdam, North Holland, Netherlands
Education
University of Groningen
Degree Name PhD Field Of Study pharmacy, pharma co economics
Dates attended or expected graduation2000 – 2003
linkedin
Disease Prevention 2021 - Day 1 @ 13:00
FIRESIDE CHAT: A pancoronavirus vaccine - how realistic, reliable, scaleable, and translatable would this be?
·How realistic is a pancoronavirus vaccine, and how vital is it?·Issues of global accessibility for a pancoronavirus vaccine·The danger of future coronavirus pandemics and why we need more funding for pancoronavirus vaccines
Maria Elena Bottazzi, Co-Director, Texas Children’s Hospital Center for Vaccine Development, Baylor College of Medicine
Pamela Bjorkman, David Baltimore Professor of Biology and Biological Engineering, California Institute of Technology
https://www.terrapinn.com/conference/disease-prevention-control-summit-america/speaker-pamela-BJORKMAN.stm
Yes, Please put it out in public all questions, Go's for all here as well!
Page A1 | e-Edition | standardspeaker.com
www.standardspeaker.com › eedition › page-a1
July 03, 2021; July 02, 2021; July 01, 2021 ... a virus expert at Baylor College of Medicine, and her colleagues applied for support from the U.S. government to develop a pancoronavirus vaccine
https://www.standardspeaker.com/eedition/page-a1/page_589a2c69-f2b1-56e7-8541-f741751dc1c3.html
Did not want to Join to get this!!
Swiss Institute for Experimental Cancer Research (ISREC) , Chemin des Boveresses 155, Epalinges, 1066, Switzerland
Mario Amacker, Nathalie Simon-Vermot & Joachim Lingner
https://www.nature.com/articles/ng0299_220#Abs1
ISREC – Swiss Institute for Experimental Cancer Research
https://www.epfl.ch/schools/sv/isrec/
ISREC Foundation
https://www.isrec.ch/accueil
University of Copenhagen
Mads Hald Andersen
Clinical Professor
Immunology
Blegdamsvej 3B, Building: 07-12-86
2200 København N.
mads.hald.andersen@regionh.dk
https://isim.ku.dk/staff/?pure=en%2Fpersons%2Fmads-hald-andersen(f6dda437-480e-4d5e-b0a3-3287c9d2372a)%2Fcv.html
Effectiveness evaluation of dendritic cell immunotherapy for ...
www.researchgate.net › publication › 282608534
Oct 05, 2015 · Mads Hald Andersen; ... Sendai virosomes can deliver encapsulated contents into the cytoplasm directly in a virus fusion-dependent manner. In this paper, Sendai virosomes-formulated melanoma
https://www.researchgate.net/publication/6749821_Enhanced_immune_responses_induced_by_vaccine_using_Sendai_virosomes_as_carrier
Founders - IO Biotech
www.iobiotech.com › index › home
Founder, Professor Mads Hald Andersen. Professor and Director of CCIT (Center for Cancer Immune Therapy at Herlev University Hospital. Mads Hald Andersen has received several honors for his scientific work and is the author of more than 130 papers. MHA has founded and co-founded several spin out companies with a successful sale of Survac in 2006.
https://www.iobiotech.com/index.php/home/founders
Reinhard Glück
Consultant
Company Name VaxBio Self-employed
Dates Employed Dec 2019 – Present
Employment Duration1 yr 8 mos
Location Oxford, England, United Kingdom
Biotechnology
UAE entrepreneur pledges AED 5 million towards COVID-19 vaccine currently in trial
Chairman of the UAE’s IBC Group is working with the UK biotech research company, Vaxbio to launch an affordable vaccine that the company hopes to launch by the summer.
https://www.mobihealthnews.com/news/emea/uae-entrepreneur-pledges-aed-5-million-towards-covid-19-vaccine-currently-trial
VaxBio (Deutschland) GmbH
VaxBio is a new German Pharma company with a substantial portfolio of Vaccine Assets and a Covid-19 candidate. After being in stealth mode for 12 months, VaxBio is now connecting with the market. VaxBio has a strong science team with a track record and a clear roadmap for growth. We are now ready to seek investments from strategic investors understanding the business domain or significant investors seeking potentially high returns from VaxBio’s patented Covid-19 vaccine based on recombinant protein subunit technology. Potential IPO in the future.
https://www.britishherald.com/vaxbio-works-on-covid-19-vaccine/
The team producing the vaccine against the SARS-CoV-2 virus is being led by Prof Reinhard Glück with efforts from senior scientists Dr Gaurav Gupta and Dr Li Yuanyuan from the University of Oxford.
The vaccine has been fast-tracked and is already undergoing testing on animals to understand its effectiveness and to monitor possible side-effects if any. The idea is to get the COVID-19 vaccine ready by summer and that means that it should have to move into the Clinical Trials 1 and 2 very soon.
Reinhard Gluck is the master / what's happening with mymx kemps
WORLD
Some Vaccinated People Are Dying of Covid-19. Here’s Why Scientists Aren’t Surprised.
Vaccines aren’t 100% effective, so some people will be vulnerable to the virus even after receiving two shots
https://www.wsj.com/articles/some-vaccinated-people-are-dying-of-covid-19-heres-why-scientists-arent-surprised-11625227200
UNIVERSAL COVID VACCINE IS THE ANSWER / DO WE MYMX HAVE IT?
(PDF) How can nanotechnology help to combat COVID-19 ...
www.researchgate.net › publication › 344133841_How
Sep 05, 2020 · through an electrospray and aqueous suspension ioniza- ... ticles, virus-like par ticles, virosomes, lip osomes, emul-sions, proteins and immune-stimulating complexes, have .
https://www.researchgate.net/publication/344133841_How_can_nanotechnology_help_to_combat_COVID-19_Opportunities_and_urgent_need